We identified a leading COVID-19 treatment that is now FDA approved

In early 2020, a specialist team of BenevolentAI researchers identified a potential COVID-19 treatment using our Knowledge Graph and AI tools.

Latest News | FDA converts emergency approval of Baricitinib to a full approval

Read more

RAPID RESPONSE

Pivoting our focus to decipher the novel coronavirus 

In January 2020, as the pandemic spread, we set out to find an existing drug that could be repurposed as a COVID-19 treatment. Although we designed our technology to develop new drugs for disease — not identify new uses for existing medications — we could make this pivot thanks to our comprehensive data foundations and flexible, disease-agnostic approach. 

NOVEL INSIGHTS

Uncovering a leading COVID-19 treatment in just 48 hours

BenevolentAI scientists used our tools to search the Knowledge Graph for mechanisms related to viral infection and inflammatory response. They identified baricitinib — a drug owned by Eli Lilly and approved for rheumatoid arthritis — as the strongest candidate.1 This hypothesis was based on novel information extracted from published literature using our Platform that baricitinib could have an off-target antiviral effect in addition to being a well-known anti-inflammatory.

The whole process took just 48 hours.

LIFE-SAVING BENEFITS

Repeated validation from randomised controlled trials

Our hypothesis was proven true. Data from four randomised controlled trials confirmed that baricitinib is a safe and effective treatment for severe COVID-19,2 with the COV-BARRIER trial showing that baricitinib plus standard of care reduced deaths by 38% across hospitalised adult patients.3 

Both the World Health Organization4 and the FDA5 have recommended the use of baricitinib for hospitalised COVID-19 patients.

IMPACT

The case for augmented drug discovery

This research shows the power of augmenting human ingenuity with machine intelligence to rapidly uncover novel insights hidden deep within vast volumes of published data and research.

References

1) Richardson et al. Lancet 395, e30-e31 (2020)2.
2) Selvaraj et al. EClinicalMedicine 49, 101489 (2022)3.
3) Marconi et al. Lancet Respir Med 9, 1407-1418 (2021)4.
4) BMJ 370, m3379 (2020)5.
4) Lilly Press Release 11 May 2022